Low #PSA, high-grade #prostatecancer (Gleason 8-10) carries high mortality risk. https://t.co/05ZGcu9pda
RT @EUPatient: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features https…
RT @EUPatient: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features https…
Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features https://t.co/EUaHg3GLkk #ProstateCancer https://t.co/DkIsZSeePS
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
RT @Beam_Doc: We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate fo…
We need to do better for high-Gleason, low-PSA #prostatecancer. Thanks to @EUplatinum for highlighting our work, @UpToDate for incorporating into PCa risk strata, and @UroDocJT + Dr. Lotan for their spot-on thought provoking editorial. Download your copy
Nice article looking at this problematic group. Unsure if these patients derive much benefit from continuing ADT after typical rapid early progression. ?lots of AE 4 little gain..Clinical and Genomic Characterization of Low–PSA, High-grade Prostate Cancer
Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://t.co/KRRzuTAMq1 https://t.co/A2ZH6CwmCW
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT…
Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/BndKFiOmpT https://t.co/t4kiDYMnvU
New2Trip: Clinical & Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer https://t.co/ThZNwzVJ73
New2Trip: Clinical & Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer https://t.co/ThZNwzVJ73
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
Great trial. I would like to see an analysis of molecular subtypes in these patients https://t.co/WE8jxkRru8
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
RT @EUplatinum: Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrP…
Low-PSA, high-grade PCa has a high risk for PCa death, may not respond to ADT, and has neuroendocrine genomic features @DrPaulNguyen https://t.co/p1hxql2c2m #prostatecancer
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @StephenRameyMD: #ProstateCancer mortality for GS 8-10 (unlike GS 7) does not have a linear relationship with PSA. Instead patients wit…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS…
#ProstateCancer mortality for GS 8-10 (unlike GS 7) does not have a linear relationship with PSA. Instead patients with PSA < 2.5 had the worst outcomes and seemed less responsive to ADT. https://t.co/107clJ5Nnb
Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/NIxbGHSDJS @DrPaulNguyen https://t.co/7DHm0fkDzE
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
Aggressive cancer requires aggressive treatment, particularly in those with decades to live. https://t.co/bcxLMlfAyQ
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
RT @PCF_Science: #PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respo…
#PCFfunded study finds high-grade #ProstateCancer w/ low–PSA levels has high risk for prostate cancer death, may not respond well to androgen deprivation therapy, and is associated w/ neuroendocrine features. New treatment strategies may be warranted. http
Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer https://t.co/27oO4bbZh3
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
RT @EUplatinum: Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU…
Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade #ProstateCancer https://t.co/H2x8W1B4fU @DrPaulNguyen https://t.co/GbVglykHEv